Juno Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Non-cash stock-based compensation
Non-cash expense in connection with equity issuance
Loss from remeasurement of fair value of convertible preferred stock options
Deferred tax benefit recorded in connection with acquisition
Deferred income taxes
Change in fair value of success payment liabilities
Change in fair value of contingent consideration
Gain on initial investment in Stage
Other-than-temporary impairment on marketable securities
Other
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other assets
Accounts payable, accrued liabilities and other liabilities
Deferred revenue
Net cash provided by (used in) operating activities
Purchases of marketable securities
Tenant improvement allowance and deferred rent
Net cash (used in) provided by operating activities
INVESTING ACTIVITIES
Purchases of marketable securities and other investments
Sales and maturities of marketable securities
Acquisitions, net of cash acquired
Purchase of property and equipment
Net cash used in investing activities
Net cash (used in) provided by investing activities
FINANCING ACTIVITIES
Proceeds from public offering of common stock, net of offering costs
Proceeds from issuance of convertible preferred stock
Proceeds from issuance of common stock to strategic partner
Proceeds from employee stock purchase plan and exercise of stock options, net of tax withholdings
Proceeds from long-term borrowings, net of financing costs
Payments of long-term debt and build-to-suit lease obligation
Repurchases of common stock
Effect of exchange rate changes on cash and cash equivalents
Payments of contingent consideration related to acquisition
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
SUPPLEMENTAL CASH FLOW INFORMATION
Purchases of property and equipment included in accounts payable and accrued liabilities
Issuance of common stock for acquisitions
Issuance of common stock for success payments
Fair value of convertible preferred stock option at issuance
Amounts capitalized under build-to-suit leases

Comments